"In designing the new building, it was important to us to minimize our environmental footprint while designing a functional space that could support core research functions and state-of-the-art molecular biology research laboratories," said Daniel O'Day, President and CEO. "With the development of this new building, we have achieved these goals while creating an optimal space for our employees to focus on their ongoing contributions to improving healthcare for people around the world."
Headquartered in Pleasanton, California, Roche Molecular Diagnostics is the world leader in molecular in vitro diagnostics. A business area of Roche (Basel, Switzerland), RMD develops and manufactures innovative tests based on its Nobel Prize winning polymerase chain reaction (PCR) technology. PCR is the technology that underlies a new generation of medical diagnostics.
RMD supplies a wide array of innovative medical diagnostic products, services, and technologies to researchers, physicians, patients, hospitals and laboratories worldwide. Our marketed diagnostic tests and automated instrument platforms, and those now in development, are focused on blood screening, virology, microbiology, genomics and oncology, and sexually transmitted diseases. For a complete list of our diagnostics and blood screening products, please visit our website at http://molecular.roche.com
Headquartered in Basel, Switzerland, Roche is one of the world's
leading research-focused healthcare groups in the fields of pharmaceuticals
and diagnostics. As the world's biggest biotech company and an innovator of
products and services for the early detection, prevention, diagnosis and
treatment of diseases, the Group contributes on a broad range of fronts to
|SOURCE Roche Molecular Diagnostics|
Copyright©2008 PR Newswire.
All rights reserved